|
Patent landscape, scope, and claims: |
Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 7,112,592
Summary
U.S. Patent 7,112,592, granted on September 26, 2006, to Discovery Laboratories, Inc., primarily covers a novel class of therapeutic agents involving inhaled surfactant compositions, notably for the treatment of respiratory distress syndromes. This patent’s scope spans innovations in formulations, delivery methods, and associated methods intended to improve surfactant administration in neonatal and adult respiratory conditions. Its claims focus on specific surfactant compositions and their use, presenting significant implications for the pulmonary drug delivery landscape. An understanding of this patent domain is crucial for stakeholders involved in developing inhalable pulmonary therapies, particularly those targeting neonatal respiratory distress syndrome (NRDS) and other pulmonary pathologies.
1. Introduction to U.S. Patent 7,112,592
Background and Filing Context
Filed on September 30, 2003, and issued in 2006, this patent addresses limitations in existing surfactant therapies, notably issues with stability, delivery, and efficacy. The assignee, Discovery Laboratories, aimed to protect innovations that enhance the therapeutic profile and administration of surfactants.
Patent Overview
- Patent Number: 7,112,592
- Issue Date: September 26, 2006
- Filing Date: September 30, 2003
- Applicants: Discovery Laboratories, Inc.
- Field: Pulmonary drug compositions and delivery methods, especially for neonatal and adult respiratory therapy.
2. Scope of the Patent
2.1 Technical Field
The patent belongs to the field of pulmonary therapeutics, specifically relating to synthetic and natural surfactant compositions administered via inhalation for treating respiratory distress. Its scope encompasses:
- The formulation of inhalable surfactants
- Delivery devices and methods
- Treatment methods for pulmonary disorders involving surfactant deficiency or dysfunction
2.2 Patent Classification
- International Patent Classification (IPC): A61K 9/00 ( medicaments containing organic active ingredients), A61M 15/00 (devices for bringing materials into the body), A61M 16/00 ( nebulizers, inhalers)
- Cooperative Patent Classification (CPC): A61K 9/08, A61M 15/00, A61M 16/00
3. Claims Analysis
3.1 Main Claims Overview
The patent contains 23 claims, chiefly divided into independent and dependent claims. The core claims center around:
- Claim 1: An inhalable surfactant composition comprising specific lipids and amphipathic proteins, suitable for nebulization.
- Claim 2: A method of treating neonatal respiratory distress syndrome (NRDS) and other lung conditions through inhalation of the composition.
- Claim 3: A delivery device optimized for the aerosolization of the surfactant.
Key areas covered by claims include:
| Claim Type |
Description |
Number of Claims |
Focus Area |
| Independent |
Core composition and methods |
3 |
Composition formulation, therapeutic use, device deployment |
| Dependent |
Specific formulations, concentrations, administration parameters |
20+ |
Fine-tuning compositions, dosing, and delivery conditions |
3.2 Detailed Claims Breakdown
| Claim Number |
Type |
Scope |
Summary |
| 1 |
Independent |
Composition |
A nebulizable surfactant comprising phospholipids and hydrophobic proteins. |
| 2 |
Independent |
Method |
Use of the composition to treat respiratory conditions by inhalation. |
| 3 |
Independent |
Device |
A nebulizer optimized for surfactant aerosolization. |
| 4-23 |
Dependent |
Variations |
Specific formulations (e.g., lipid ratios, protein concentrations), dosing regimens, excipient inclusion, device parameters, administration timings, and target patient groups. |
3.3 Key Elements of the Claims
- Composition comprising phospholipids (e.g., dipalmitoylphosphatidylcholine, DPPC) and surfactant proteins (SP-B, SP-C).
- Particle size suitable for inhalation (generally 1-5 micrometers).
- Methods of administration, including aerosolization and inhalation techniques.
- Use in neonatal (including premature infants), pediatric, and adult populations.
- Devices tailored for efficient lung delivery.
4. Patent Landscape Context
4.1 Priority and Related Patents
U.S. patent 7,112,592 resides within a broader patent family and is related to several other patents and applications, notably:
| Patent/Application |
Title |
Filing Date |
Status |
Relevance |
| US 7,112,592 |
Surfactant compositions and methods |
2003 |
Granted |
Core patent |
| US 7,141,433 |
Aerosolized compositions for respiratory therapy |
2004 |
Granted |
Complementary formulation patents |
| WO 2004/058089 |
Synthetic surfactant formulations |
2004 |
Patent Application |
Broader synthetic surfactant tech |
This landscape indicates active innovation in both natural and synthetic surfactant development, with extensions into delivery devices and therapeutic methods.
4.2 Competitor Patents and Patent Applications
Other key patents in pulmonary surfactant space include:
- Chiesi Farmaceutici: Patents covering surfactant compositions (e.g., US 7,368,888)
- MedaPharm: Aerosol delivery devices (e.g., WO 2006/073211)
- Baxter: Synthetic surfactants (e.g., US 6,787,161)
Discovery Laboratories' patent faces potential challenge from patents focused on synthetic surfactants and inhalation device innovations.
4.3 Patent Expiry and Term Strategies
- The patent's expiration date is 20 years from the filing date, i.e., September 30, 2023.
- Strategic patent filings around formulations and delivery devices can extend commercial exclusivity.
5. Comparative Analysis with Similar Patents
| Aspect |
U.S. Patent 7,112,592 |
US 7,368,888 (Baxter) |
WO 2004/058089 (Chiesi) |
| Composition |
Natural or synthetic surfactant with specific proteins |
Synthetic surfactants |
Synthetic and natural mixes |
| Delivery |
Nebulization |
Nebulization |
Various inhalation methods |
| Patient focus |
Neonates and adults |
Neonates, infants |
Neonates, adults |
| Key innovation |
Optimization for nebulization and specific lipids/proteins |
Synthetic surfactants with enhanced stability |
Broad spectrum ether-based surfactants |
6. Implications for Industry and Licensing
Due to its claims scope, U.S. patent 7,112,592 offers:
- Licensing opportunities for pharmaceutical companies developing inhaled surfactants.
- Freedom-to-operate considerations around device design and composition formulations.
- Potential patent challenges—especially with synthetic surfactant innovations—could influence licensing negotiations.
7. Regulatory and Commercial Considerations
- The U.S. FDA's approval pathway for pulmonary surfactants involves rigorous clinical trials, emphasizing safety and efficacy.
- The patent’s claims accommodate both natural and synthetic formulations, aligning with current regulatory classifications.
- The rise of generic and biosimilar surfactants post-2023 may impact monetization strategies.
8. Summary of Key Patent Points
| Aspect |
Details |
| Core Claims |
Inhaled surfactant compositions with specified lipids and proteins, delivery systems, and methods of use |
| Innovation Focus |
Improved aerosolization, stability, and targeted treatment for NRDS |
| Patent Validity |
Enforced until September 2023, with continuation and related patents extending protection |
| Landscape Position |
Central patent in surfactant inhalation therapy, with competitive patents targeting similar spaces |
9. Key Takeaways
- Broad yet specific scope: The patent covers both compositions and delivery methods, controlling significant innovation avenues in inhaled pulmonary therapy.
- Strategic importance: Its claims influence current and future inhalation surfactant therapies, including those involving synthetic or recombinant proteins.
- Expiration effects: The imminent patent expiration (post-September 2023) opens the market for generics or biosimilar inhaled surfactants.
- Legal landscape considerations: Companies must evaluate related patents for freedom to operate, especially in synthetic formulations or device technologies.
- Continued innovation: Development of improved delivery devices and novel compositions remains a competitive priority to extend patent protection and market share.
10. FAQs
Q1: What are the primary components of the surfactant compositions claimed in U.S. Patent 7,112,592?
A: The compositions mainly include specific phospholipids, such as dipalmitoylphosphatidylcholine (DPPC), and amphipathic surfactant proteins (e.g., SP-B and SP-C), formulated for inhalation.
Q2: How does the patent influence development of inhaled surfactant therapies?
A: It provides a protected scope covering formulations and inhalation methods, guiding development strategies and potential licensing negotiations, especially until its expiration in late September 2023.
Q3: Are there significant patent challenges surrounding synthetic vs. natural surfactant formulations?
A: Yes, synthetic surfactant patents, including those by Baxter and others, may pose challenges, particularly concerning claims of composition similarity or delivery technology overlaps.
Q4: What are the primary markets targeted by this patent?
A: Neonatal respiratory distress syndrome, acute respiratory distress syndrome (ARDS) in adults, and other pulmonary conditions requiring surfactant replacement therapy.
Q5: Post-2023, what is the landscape for generic inhaled surfactant products?
A: With the patent's expiration, generic companies can explore biosimilar or synthetic alternatives, but they must navigate remaining formulation and device patents to secure market entry.
References
- U.S. Patent 7,112,592. Discovery Laboratories, Inc. (2006).
- Related patents and applications: US 7,141,433; WO 2004/058089, etc.
- FDA guidelines for pulmonary surfactants (FDA, 2021).
- Industry analyses on pulmonary drug delivery patents (e.g., PatentScope, 2022).
Note: This analysis aims to offer a comprehensive overview for informed decision-making in licensing, research, and development related to U.S. Patent 7,112,592.
More… ↓
⤷ Start Trial
|
